Background:
Aducanumab, or BIIB037, is a monoclonal IgG1 antibody that targets extracellular amyloid- plaques in the brain; similar to gantenerumab, bapineuzumab and solanezumab.Aducanumab is a recombinant antibody derived from patients with slow or absent cognitive decline, and phase 1b clinical trial data have shown patients treated with aducanumab show a reduction in amyloid- plaques.Based on Mini-Mental State Examination and Clinical Dementia Rating (CDR), patients taking aducanumab showed signs of slowing progression, however, these data are controversial.Clinical trials showed a 23% relative difference between the experimental and placebo groups as determined by CDR. Aducanumab is a monoclonal antibody indicated in the treatment of Alzheimer’s disease.
Intended Use:
For Estimation of Aducanumab in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Aducanumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Aducanumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Aducanumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Aducanumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!
